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LETTERS
Variant Creutzfeldt-Jakob
disease in older patients
Variant Creutzfeldt-Jakob disease (vCJD)
is a zoonotic disease caused by cross-
species transmission of bovine spongiform
encephalopathy with a median age at
onset of 27 years. In 1996, when the ﬁrst
cases were described, a clinicopathological
phenotype distinct from sporadic CJD
was deﬁned and diagnostic criteria with a
high sensitivity and speciﬁcity for vCJD
have been validated.1
All deﬁnite and probable cases of vCJD
(201/218) have been methionine homozy-
gous (MM) at codon 129 of the prion
protein gene (PRNP). If cases with the
other PRNP-129 genotypes (MV, VV)
have longer incubation periods, and are
exposed at the same age, they will be
older by the time they develop symptom-
atic disease. In addition, patients over 50
are more likely undergo surgical proce-
dures and receive blood transfusions than
younger patients and are, therefore, at
greater risk of secondary vCJD. Future
vCJD cases are likely to occur in older
groups than in the primary epidemic. An
important question is whether these
patients have the same clinical phenotype
and pattern of investigation ﬁndings as
previously described.
A review of the 177 probable and deﬁn-
ite vCJD cases referred to the UK surveil-
lance system between 1995 and 2014
identiﬁed six cases aged over 55 years at
the onset of symptoms.
All the cases developed progressive cog-
nitive impairment and additional neuro-
logical features which are unusual in the
more common forms of dementia in the
middle-aged and elderly. Four had invol-
untary movements, three sensory symp-
toms and ﬁve ataxia, with the sixth case
exhibiting an apraxic gait. Only three
cases had early psychiatric symptoms, but
withdrawal and behavioural disturbance
were seen later in the clinical course in
two cases (table 1). Only one of the ﬁve
cases with MRI brain imaging showed
typical pulvinar high signal,2 with another
showing less typical abnormalities. One
case underwent a tonsil biopsy, which was
positive for vCJD-related abnormal prion
protein. Two of the older cases fulﬁlled
the current WHO clinical criteria for a
diagnosis in life of probable vCJD and
two for possible vCJD. The ﬁnal two
cases did not fulﬁl criteria for either prob-
able or possible vCJD but all the cases
were conﬁrmed neuropathologically with T
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typical features of vCJD, including depos-
ition of type 2B prion protein. DNA was
extracted from postmortem tissue and all
cases were MM at codon 129 of PRNP.
Two cases respectively were initially
referred to neurology, general medicine
and geriatrics and ﬁve out of the six cases
were seen by a neurologist at some stage
during the clinical illness. Two of the
cases were diagnosed as probable vCJD in
life: the second transfusion recipient who
was clinically atypical of vCJD, but had a
positive tonsil biopsy and a case with
typical clinical features and a positive
MRI brain. One case diagnosed as multi-
infarct dementia fulﬁlled the clinical cri-
teria for possible vCJD, but did not
undergo an MRI brain or tonsil biopsy. In
two cases, the ﬁnal clinical diagnosis was
frontotemporal dementia (FTD) and, in
the ﬁnal case, Wernicke’s encephalopathy.
The data in this paper indicate that a
small proportion of cases of vCJD have
occurred in relatively older age groups.
The National CJD Research &
Surveillance Unit (NCJDRSU) has identi-
ﬁed six cases of vCJD aged over 55 years,
with a mean age at onset of 61 years,
which contrasts with the overall mean age
at onset in vCJD of 27 years (n=171).
The older cases occurred relatively late in
the vCJD outbreak overall, but there is no
indication of a trend to an increase in the
number of older cases with time.
There may be a diagnostic challenge in
recognising these older vCJD cases among
a population with a high overall incidence
of dementia. All had a progressive history
of cognitive impairment with four cases
exhibiting a rapidly evolving dementia over
1 year. The rapidity of the ﬁnal deterior-
ation raised the suspicion of sporadic CJD
in some of the cases. All had other neuro-
logical features suggestive of a dementia dif-
ferent from the common causes in their age
group, such as involuntary movements,
sensory symptoms or ataxia, but only two
cases had sufﬁcient clinical features to fulﬁl
the criteria for probable vCJD. One of
these cases had a typical MRI for vCJD and
was diagnosed in life and one was recog-
nised as vCJD in the context of being
known to be at risk through a prior impli-
cated blood transfusion.
The other four cases were not diagnosed
in life with two being thought to have FTD,
one multi-infarct dementia and one
Wernicke’s encephalopathy. In one of the
cases initially diagnosed as FTD, the possi-
bility of ‘prion disease’ was raised following
a rapid decline and a repeat MRI was
planned, but was not carried out. In three
other cases the possibility of ‘CJD’ was men-
tioned in the case records after a rapid
decline in the late stages of the illness. Thus,
although vCJD was only diagnosed in life in
two cases, the possibility of CJD or prion
disease was raised in three other cases.
This report describes six pathologically
conﬁrmed cases of vCJD over the age of
55 years with a less consistent clinical
phenotype than has been described in
younger patients. The characteristic MRI
pulvinar sign was seen in only one case.
There a risk of the diagnosis being missed
in older vCJD cases, particularly if
patients are seen by specialties with less
awareness of the clinical and investigative
features of vCJD. Differentiating vCJD
from other forms of subacute dementia in
an older population with a higher back-
ground prevalence of dementia may be
problematic and it is important to be
aware that vCJD can occur in older age
groups.3 4 The diagnosis of vCJD should
be considered in patients with atypical
forms of dementia involving ataxia and/or
involuntary movements and a rapid
course or acute terminal deterioration.
Repeat MRI or tonsil biopsy may be indi-
cated if there is a suspicion of vCJD and
postmortem in a regional neuropathology
centres with expertise in CJD should be
considered in such cases.5
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